

By Senator Rouson

19-00569-17

2017424__

1 A bill to be entitled
2 An act relating to controlled substances; amending s.
3 893.03, F.S.; scheduling Mitragynine and 7-
4 Hydroxymitragynine, constituents of Kratom, in a
5 schedule of controlled substances; scheduling isomers,
6 esters, ethers, salts, and salts of isomers, esters,
7 and ethers of Mitragynine and 7-Hydroxymitragynine in
8 a schedule of controlled substances; providing an
9 exception from scheduling for any drug product
10 approved by the United States Food and Drug
11 Administration which contains Mitragynine or 7-
12 Hydroxymitragynine; amending s. 893.13, F.S.;
13 providing a criminal penalty; reenacting s.
14 39.01(30)(a) and (g), F.S., relating to definitions
15 used in ch. 39, F.S., s. 316.193(5), F.S., relating to
16 driving under the influence, s. 322.2616(2)(c), F.S.,
17 relating to suspension of driver licenses, s.
18 327.35(5), F.S., relating to boating under the
19 influence, s. 440.102(11)(b), F.S., relating to drug-
20 free workplace programs, ss. 458.3265(1)(e) and
21 459.0137(1)(e), F.S., relating to pain-management
22 clinics, s. 782.04(1)(a) and (4), F.S., relating to
23 murder, s. 787.06(2)(a), F.S., relating to human
24 trafficking, s. 817.563, F.S., relating to sale of
25 substance in lieu of a controlled substance, s.
26 831.31(1)(a) and (2), F.S., relating to counterfeit
27 controlled substance, s. 856.015(1)(c), F.S., relating
28 to open house parties, s. 893.02(4), F.S., relating to
29 definitions used in ch. 893, F.S., ss. 893.035(2),
30 (7)(a), and (8)(a) and 893.0356(2)(a) and (5), F.S.,
31 relating to control of new substances, s.
32 893.05(1)(d), F.S., relating to practitioners and

19-00569-17

2017424__

33 persons administering controlled substances in their
34 absence, s. 893.12(2)(b), (c), and (d), F.S., relating
35 to contraband, seizure, forfeiture, and sale, s.
36 893.13(1)(a), (c), (d), (e), (f), and (h), (2)(a),
37 (4)(b), (5)(b), and (7)(a), F.S., relating to
38 prohibited acts and penalties, and 921.0022(3)(b),
39 (c), and (e), F.S., relating to the offense severity
40 ranking chart of the Criminal Punishment Code, to
41 incorporate the amendment made by the act to s.
42 893.03, F.S., in references thereto; providing an
43 effective date.

44
45 Be It Enacted by the Legislature of the State of Florida:

46
47 Section 1. Paragraph (c) of subsection (1) of section
48 893.03, Florida Statutes, is amended to read:

49 893.03 Standards and schedules.—The substances enumerated
50 in this section are controlled by this chapter. The controlled
51 substances listed or to be listed in Schedules I, II, III, IV,
52 and V are included by whatever official, common, usual,
53 chemical, trade name, or class designated. The provisions of
54 this section shall not be construed to include within any of the
55 schedules contained in this section any excluded drugs listed
56 within the purview of 21 C.F.R. s. 1308.22, styled "Excluded
57 Substances"; 21 C.F.R. s. 1308.24, styled "Exempt Chemical
58 Preparations"; 21 C.F.R. s. 1308.32, styled "Exempted
59 Prescription Products"; or 21 C.F.R. s. 1308.34, styled "Exempt
60 Anabolic Steroid Products."

61 (1) SCHEDULE I.—A substance in Schedule I has a high

19-00569-17

2017424__

62 potential for abuse and has no currently accepted medical use in
63 treatment in the United States and in its use under medical
64 supervision does not meet accepted safety standards. The
65 following substances are controlled in Schedule I:

66 (c) Unless specifically excepted or unless listed in
67 another schedule, any material, compound, mixture, or
68 preparation that contains any quantity of the following
69 hallucinogenic substances or that contains any of their salts,
70 isomers, including optical, positional, or geometric isomers,
71 homologues, nitrogen-heterocyclic analogs, esters, ethers, and
72 salts of isomers, homologues, nitrogen-heterocyclic analogs,
73 esters, or ethers, if the existence of such salts, isomers, and
74 salts of isomers is possible within the specific chemical
75 designation or class description:

- 76 1. Alpha-Ethyltryptamine.
- 77 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2-
78 oxazoline).
- 79 3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
- 80 4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
- 81 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
- 82 6. Bufotenine.
- 83 7. Cannabis.
- 84 8. Cathinone.
- 85 9. DET (Diethyltryptamine).
- 86 10. 2,5-Dimethoxyamphetamine.
- 87 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
- 88 12. DMT (Dimethyltryptamine).
- 89 13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine analog
90 of phencyclidine).

19-00569-17

2017424__

- 91 14. JB-318 (N-Ethyl-3-piperidyl benzilate).
92 15. N-Ethylamphetamine.
93 16. Fenethylamine.
94 17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
95 18. Ibogaine.
96 19. LSD (Lysergic acid diethylamide).
97 20. Mescaline.
98 21. Methcathinone.
99 22. 5-Methoxy-3,4-methylenedioxyamphetamine.
100 23. PMA (4-Methoxyamphetamine).
101 24. PMMA (4-Methoxymethamphetamine).
102 25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
103 26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
104 27. MDA (3,4-Methylenedioxyamphetamine).
105 28. JB-336 (N-Methyl-3-piperidyl benzilate).
106 29. N,N-Dimethylamphetamine.
107 30. Parahexyl.
108 31. Peyote.
109 32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
110 analog of phencyclidine).
111 33. Psilocybin.
112 34. Psilocyn.
113 35. *Salvia divinorum*, except for any drug product approved
114 by the United States Food and Drug Administration which contains
115 *Salvia divinorum* or its isomers, esters, ethers, salts, and
116 salts of isomers, esters, and ethers, if the existence of such
117 isomers, esters, ethers, and salts is possible within the
118 specific chemical designation.
119 36. Salvinorin A, except for any drug product approved by

19-00569-17

2017424__

120 the United States Food and Drug Administration which contains
121 Salvinorin A or its isomers, esters, ethers, salts, and salts of
122 isomers, esters, and ethers, if the existence of such isomers,
123 esters, ethers, and salts is possible within the specific
124 chemical designation.

125 37. Xylazine.

126 38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)
127 (Thiophene analog of phencyclidine).

128 39. 3,4,5-Trimethoxyamphetamine.

129 40. Methylone (3,4-Methylenedioxymethcathinone).

130 41. MDPV (3,4-Methylenedioxypropylone).

131 42. Methylmethcathinone.

132 43. Methoxymethcathinone.

133 44. Fluoromethcathinone.

134 45. Methylethcathinone.

135 46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-
136 yl)phenol) and its dimethyloctyl (C8) homologue.

137 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-
138 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].

139 48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).

140 49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).

141 50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-
142 naphthoyl)indole).

143 51. BZP (Benzylpiperazine).

144 52. Fluorophenylpiperazine.

145 53. Methylphenylpiperazine.

146 54. Chlorophenylpiperazine.

147 55. Methoxyphenylpiperazine.

148 56. DBZP (1,4-Dibenzylpiperazine).

19-00569-17

2017424__

- 149 57. TFMPP (Trifluoromethylphenylpiperazine).
150 58. MBDB (Methylbenzodioxolylbutanamine) or (3,4-
151 Methylenedioxy-N-methylbutanamine).
152 59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
153 60. 5-Hydroxy-N-methyltryptamine.
154 61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
155 62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
156 63. Methyltryptamine.
157 64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
158 65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
159 66. Tyramine (4-Hydroxyphenethylamine).
160 67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
161 68. DiPT (N,N-Diisopropyltryptamine).
162 69. DPT (N,N-Dipropyltryptamine).
163 70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
164 71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
165 72. DOI (4-Iodo-2,5-dimethoxyamphetamine).
166 73. DOC (4-Chloro-2,5-dimethoxyamphetamine).
167 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
168 75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
169 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
170 77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
171 78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
172 79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
173 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
174 81. Butylone (3,4-Methylenedioxy-alpha-
175 methylaminobutyrophenone).
176 82. Ethcathinone.
177 83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).

19-00569-17

2017424__

- 178 84. Naphyrone (Naphthylpyrovalerone).
179 85. Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone).
180 86. 3,4-Methylenedioxy-N,N-diethylcathinone.
181 87. 3,4-Methylenedioxy-propiofenone.
182 88. 3,4-Methylenedioxy-alpha-bromopropiofenone.
183 89. 3,4-Methylenedioxy-propiofenone-2-oxime.
184 90. 3,4-Methylenedioxy-N-acetylcathinone.
185 91. 3,4-Methylenedioxy-N-acetylmethcathinone.
186 92. 3,4-Methylenedioxy-N-acetylethcathinone.
187 93. Bromomethcathinone.
188 94. Buphedrone (alpha-Methylamino-butyrophenone).
189 95. Eutylone (3,4-Methylenedioxy-alpha-
190 ethylaminobutyrophenone).
191 96. Dimethylcathinone.
192 97. Dimethylmethcathinone.
193 98. Pentylone (3,4-Methylenedioxy-alpha-
194 methylaminovalerophenone).
195 99. MDPMP (3,4-Methylenedioxy-alpha-
196 pyrrolidinopropiofenone).
197 100. MDPBP (3,4-Methylenedioxy-alpha-
198 pyrrolidinobutyrophenone).
199 101. MOPMP (Methoxy-alpha-pyrrolidinopropiofenone).
200 102. MPPH (Methyl-alpha-pyrrolidinohexanophenone).
201 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
202 (Benocyclidine).
203 104. F-MABP (Fluoromethylaminobutyrophenone).
204 105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
205 106. Et-PBP (Ethylpyrrolidinobutyrophenone).
206 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).

19-00569-17

2017424__

- 207 108. Me-EABP (Methylethylaminobutyrophenone).
208 109. Etizolam.
209 110. PPP (Pyrrolidinopropiophenone).
210 111. PBP (Pyrrolidinobutyrophenone).
211 112. PVP (Pyrrolidinovalerophenone) or
212 (Pyrrolidinopentiophenone).
213 113. MPPP (Methyl-alpha-pyrrolidinopropiophenone).
214 114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
215 115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
216 116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
217 117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
218 118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
219 119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
220 120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
221 121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-
222 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
223 122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
224 123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
225 124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
226 125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
227 126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
228 127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
229 128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
230 129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
231 130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-
232 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
233 ol).
234 131. HU-308 ([(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-methyloctan-
235 2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]

19-00569-17

2017424__

236 methanol).

237 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1-

238 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-

239 1,4-dione).

240 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene).

241 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)-

242 undecanamide).

243 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)-

244 undecanamide).

245 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2-

246 methyloctan-2-yl)phenol).

247 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).

248 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).

249 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).

250 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2-

251 methoxyphenylacetyl)indole).

252 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-

253 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-

254 naphthalenylmethanone).

255 142. WIN55,212-3 ([3S)-2,3-Dihydro-5-methyl-3-(4-

256 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-

257 naphthalenylmethanone).

258 143. Pentedrone (alpha-Methylaminovalerophenone).

259 144. Fluoroamphetamine.

260 145. Fluoromethamphetamine.

261 146. Methoxetamine.

262 147. Methiopropamine.

263 148. Methylbuphedrone (Methyl-alpha-

264 methylaminobutyrophenone).

19-00569-17

2017424__

- 265 149. APB ((2-Aminopropyl)benzofuran) .
- 266 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran) .
- 267 151. UR-144 (1-Pentyl-3-(2,2,3,3-
- 268 tetramethylcyclopropanoyl)indole) .
- 269 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-
- 270 tetramethylcyclopropanoyl)indole) .
- 271 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-
- 272 tetramethylcyclopropanoyl)indole) .
- 273 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide) .
- 274 155. AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-
- 275 iodobenzoyl)indole) .
- 276 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-
- 277 carboxamide) .
- 278 157. URB-597 ((3'-(Aminocarbonyl)[1,1'-biphenyl]-3-yl)-
- 279 cyclohexylcarbamate) .
- 280 158. URB-602 ([1,1'-Biphenyl]-3-yl-carbamic acid,
- 281 cyclohexyl ester) .
- 282 159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1-
- 283 benzoxazin-4-one) .
- 284 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine) .
- 285 161. 2C-H (2,5-Dimethoxyphenethylamine) .
- 286 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine) .
- 287 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine) .
- 288 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-
- 289 methoxybenzyl)]phenethylamine) .
- 290 165. MDMA (3,4-Methylenedioxymethamphetamine) .
- 291 166. PB-22 (8-Quinolinyll 1-pentylindole-3-carboxylate) .
- 292 167. Fluoro PB-22 (8-Quinolinyll 1-(fluoropentyl)indole-3-
- 293 carboxylate) .

19-00569-17

2017424__

- 294 168. BB-22 (8-Quinoliny 1-(cyclohexylmethyl)indole-3-
295 carboxylate).
- 296 169. Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole-
297 3-carboxamide).
- 298 170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
299 pentylindazole-3-carboxamide).
- 300 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
301 (4-fluorobenzyl)indazole-3-carboxamide).
- 302 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-
303 1-pentylindazole-3-carboxamide).
- 304 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
305 yl)-1-(fluoropentyl)indole-3-carboxamide).
- 306 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-
307 methoxybenzyl)]phenethylamine).
- 308 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-
309 methoxybenzyl)]phenethylamine).
- 310 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
311 (cyclohexylmethyl)indazole-3-carboxamide).
- 312 177. FUB-PB-22 (8-Quinoliny 1-(4-fluorobenzyl)indole-3-
313 carboxylate).
- 314 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole-
315 3-carboxamide).
- 316 179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-
317 (fluoropentyl)indazole-3-carboxamide).
- 318 180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole).
- 319 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl-
320 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).
- 321 182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9-
322 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-

19-00569-17

2017424__

323 hexahydrobenzo[c]chromen-1-ol).

324 183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9-

325 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-

326 hexahydrobenzo[c]chromen-1-ol).

327 184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)-

328 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9

329 diol).

330 185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6-

331 dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-

332 tetrahydro-6aH-benzo[c]chromen-1-ol).

333 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl-

334 6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).

335 187. MAPB ((2-Methylaminopropyl)benzofuran).

336 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).

337 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).

338 190. Synthetic Cannabinoids.—Unless specifically excepted

339 or unless listed in another schedule or contained within a

340 pharmaceutical product approved by the United States Food and

341 Drug Administration, any material, compound, mixture, or

342 preparation that contains any quantity of a synthetic

343 cannabinoid found to be in any of the following chemical class

344 descriptions, or homologues, nitrogen-heterocyclic analogs,

345 isomers (including optical, positional, or geometric), esters,

346 ethers, salts, and salts of homologues, nitrogen-heterocyclic

347 analogs, isomers, esters, or ethers, whenever the existence of

348 such homologues, nitrogen-heterocyclic analogs, isomers, esters,

349 ethers, salts, and salts of isomers, esters, or ethers is

350 possible within the specific chemical class or designation.

351 Since nomenclature of these synthetically produced cannabinoids

19-00569-17

2017424__

352 is not internationally standardized and may continually evolve,
353 these structures or the compounds of these structures shall be
354 included under this subparagraph, regardless of their specific
355 numerical designation of atomic positions covered, if it can be
356 determined through a recognized method of scientific testing or
357 analysis that the substance contains properties that fit within
358 one or more of the following categories:

359 a. Tetrahydrocannabinols.—Any tetrahydrocannabinols
360 naturally contained in a plant of the genus *Cannabis*, the
361 synthetic equivalents of the substances contained in the plant
362 or in the resinous extracts of the genus *Cannabis*, or synthetic
363 substances, derivatives, and their isomers with similar chemical
364 structure and pharmacological activity, including, but not
365 limited to, Delta 9 tetrahydrocannabinols and their optical
366 isomers, Delta 8 tetrahydrocannabinols and their optical
367 isomers, Delta 6a,10a tetrahydrocannabinols and their optical
368 isomers, or any compound containing a tetrahydrobenzo[c]chromene
369 structure with substitution at either or both the 3-position or
370 9-position, with or without substitution at the 1-position with
371 hydroxyl or alkoxy groups, including, but not limited to:

372 (I) Tetrahydrocannabinol.

373 (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-
374 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
375 ol).

376 (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-
377 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
378 ol).

379 (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-
380 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

19-00569-17

2017424__

- 381 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-
382 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
- 383 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan-
384 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
- 385 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-(2,3-
386 dimethylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
- 387 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)-
388 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
- 389 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl-
390 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
- 391 (X) Parahexyl.
- 392 b. Naphthoylindoles, Naphthoylindazoles,
393 Naphthoylcarbazoles, Naphthylmethylindoles,
394 Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any
395 compound containing a naphthoylindole, naphthoylindazole,
396 naphthoylcarbazole, naphthylmethylindole,
397 naphthylmethylindazole, or naphthylmethylcarbazole structure,
398 with or without substitution on the indole, indazole, or
399 carbazole ring to any extent, whether or not substituted on the
400 naphthyl ring to any extent, including, but not limited to:
- 401 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
- 402 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1-
403 naphthoyl)indole).
- 404 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
- 405 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).
- 406 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
- 407 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
- 408 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
- 409 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).

19-00569-17

2017424__

410 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).
411 (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
412 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
413 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).
414 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
415 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1-
416 naphthoyl)indole).
417 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole).
418 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
419 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1-
420 naphthoyl)indole).
421 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-naphthoyl)indole).
422 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
423 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl)indole).
424 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl)indole).
425 (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1-
426 naphthylmethyl]indole).
427 (XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1-
428 naphthoyl)indole).
429 (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1-
430 naphthoyl)indole).
431 (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-
432 naphthoyl)indole).
433 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
434 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole).
435 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
436 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole).
437 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole).
438 (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1-

19-00569-17

2017424__

- 439 naphthoyl)indole).
- 440 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1-
- 441 naphthoyl)indole).
- 442 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1-
- 443 naphthoyl)indole).
- 444 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1-
- 445 naphthoyl)indole).
- 446 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1-
- 447 naphthoyl)indole).
- 448 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole).
- 449 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1-
- 450 naphthoyl)indazole).
- 451 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1-
- 452 naphthoyl)indole).
- 453 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1-
- 454 naphthoyl)indole).
- 455 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole).
- 456 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1-
- 457 naphthoyl)carbazole).
- 458 c. Naphthoylpyrroles.—Any compound containing a
- 459 naphthoylpyrrole structure, with or without substitution on the
- 460 pyrrole ring to any extent, whether or not substituted on the
- 461 naphthyl ring to any extent, including, but not limited to:
- 462 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole).
- 463 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole).
- 464 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole).
- 465 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole).
- 466 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole).
- 467 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1-

19-00569-17

2017424__

468 naphthoyl)pyrrole).

469 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1-
470 naphthoyl)pyrrole).

471 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1-
472 naphthoyl)pyrrole).

473 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1-
474 naphthoyl)pyrrole).

475 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1-
476 naphthoyl)pyrrole).

477 d. Naphthylmethylenindenes.—Any compound containing a
478 naphthylmethylenindene structure, with or without substitution
479 at the 3-position of the indene ring to any extent, whether or
480 not substituted on the naphthyl ring to any extent, including,
481 but not limited to, JWH-176 (3-Pentyl-1-
482 (naphthylmethylene)indene).

483 e. Phenylacetylindoles and Phenylacetylindazoles.—Any
484 compound containing a phenylacetylindole or phenylacetylindazole
485 structure, with or without substitution on the indole or
486 indazole ring to any extent, whether or not substituted on the
487 phenyl ring to any extent, including, but not limited to:

488 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).

489 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).

490 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).

491 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).

492 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).

493 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).

494 (VII) Cannabipiperidiethanone.

495 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2-
496 methoxyphenylacetyl)indole).

19-00569-17

2017424__

497 f. Cyclohexylphenols.—Any compound containing a
498 cyclohexylphenol structure, with or without substitution at the
499 5-position of the phenolic ring to any extent, whether or not
500 substituted on the cyclohexyl ring to any extent, including, but
501 not limited to:

502 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-
503 yl)phenol).

504 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)
505 homologue).

506 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2-
507 methyloctan-2-yl)phenol).

508 g. Benzoylindoles and Benzoylindazoles.—Any compound
509 containing a benzoylindole or benzoylindazole structure, with or
510 without substitution on the indole or indazole ring to any
511 extent, whether or not substituted on the phenyl ring to any
512 extent, including, but not limited to:

513 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).

514 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).

515 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-
516 iodo-5-nitrobenzoyl)indole).

517 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-(4-
518 methoxybenzoyl)indole).

519 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-
520 iodobenzoyl)indole).

521 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).

522 (VII) RCS-4 C4 homologue (1-Butyl-3-(4-
523 methoxybenzoyl)indole).

524 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo-
525 3-(4-methoxybenzoyl)indole).

19-00569-17

2017424__

526 h. Tetramethylcyclopropanoylindoles and
527 Tetramethylcyclopropanoylindazoles.—Any compound containing a
528 tetramethylcyclopropanoylindole or
529 tetramethylcyclopropanoylindazole structure, with or without
530 substitution on the indole or indazole ring to any extent,
531 whether or not substituted on the tetramethylcyclopropyl group
532 to any extent, including, but not limited to:

533 (I) UR-144 (1-Pentyl-3-(2,2,3,3-
534 tetramethylcyclopropanoyl)indole).

535 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-
536 tetramethylcyclopropanoyl)indole).

537 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-
538 tetramethylcyclopropanoyl)indole).

539 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3-
540 tetramethylcyclopropanoyl)indole).

541 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3-
542 tetramethylcyclopropanoyl)indole).

543 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3-
544 tetramethylcyclopropanoyl)indole).

545 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3-
546 tetramethylcyclopropanoyl)indole).

547 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3-
548 tetramethylcyclopropanoyl)indazole).

549 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3-
550 tetramethylcyclopropanoyl)indole).

551 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3-
552 tetramethylcyclopropanoyl)indole).

553 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole
554 carboxamides, and Adamantylindazole carboxamides.—Any compound

19-00569-17

2017424__

555 containing an adamantoyl indole, adamantoyl indazole, adamantyl
556 indole carboxamide, or adamantyl indazole carboxamide structure,
557 with or without substitution on the indole or indazole ring to
558 any extent, whether or not substituted on the adamantyl ring to
559 any extent, including, but not limited to:

560 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).

561 (II) Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole-
562 3-carboxamide).

563 (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-
564 carboxamide).

565 (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1-
566 adamantoyl)indole).

567 (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).

568 (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).

569 (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1-
570 adamantoyl)indole).

571 j. Quinolinyllindolecarboxylates,
572 Quinolinyllindazolecarboxylates, Quinolinyllindolecarboxamides,
573 and Quinolinyllindazolecarboxamides.—Any compound containing a
574 quinolinyllindole carboxylate, quinolinyllindazole carboxylate,
575 isoquinolinyllindole carboxylate, isoquinolinyllindazole
576 carboxylate, quinolinyllindole carboxamide, quinolinyllindazole
577 carboxamide, isoquinolinyllindole carboxamide, or
578 isoquinolinyllindazole carboxamide structure, with or without
579 substitution on the indole or indazole ring to any extent,
580 whether or not substituted on the quinoline or isoquinoline ring
581 to any extent, including, but not limited to:

582 (I) PB-22 (8-Quinolinyll 1-pentylindole-3-carboxylate).

583 (II) Fluoro PB-22 (8-Quinolinyll 1-(fluoropentyl)indole-3-

19-00569-17

2017424__

584 carboxylate).

585 (III) BB-22 (8-Quinoliny 1-(cyclohexylmethyl)indole-3-

586 carboxylate).

587 (IV) FUB-PB-22 (8-Quinoliny 1-(4-fluorobenzyl)indole-3-

588 carboxylate).

589 (V) NPB-22 (8-Quinoliny 1-pentylindazole-3-carboxylate).

590 (VI) Fluoro NPB-22 (8-Quinoliny 1-(fluoropentyl)indazole-

591 3-carboxylate).

592 (VII) FUB-NPB-22 (8-Quinoliny 1-(4-fluorobenzyl)indazole-

593 3-carboxylate).

594 (VIII) THJ (8-Quinoliny 1-pentylindazole-3-carboxamide).

595 (IX) Fluoro THJ (8-Quinoliny 1-(fluoropentyl)indazole-3-

596 carboxamide).

597 k. Naphthylindolecarboxylates and

598 Naphthylindazolecarboxylates.—Any compound containing a

599 naphthylindole carboxylate or naphthylindazole carboxylate

600 structure, with or without substitution on the indole or

601 indazole ring to any extent, whether or not substituted on the

602 naphthyl ring to any extent, including, but not limited to:

603 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3-

604 carboxylate).

605 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3-

606 carboxylate).

607 (III) Fluoro SDB-005 (1-Naphthalenyl 1-

608 (fluoropentyl)indazole-3-carboxylate).

609 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3-

610 carboxylate).

611 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3-

612 carboxylate).

19-00569-17

2017424__

613 1. Naphthylindole carboxamides and Naphthylindazole
614 carboxamides.—Any compound containing a naphthylindole
615 carboxamide or naphthylindazole carboxamide structure, with or
616 without substitution on the indole or indazole ring to any
617 extent, whether or not substituted on the naphthyl ring to any
618 extent, including, but not limited to:

619 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).

620 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole-
621 3-carboxamide).

622 (III) Chloro-NNEI (N-Naphthalen-1-yl 1-
623 (chloropentyl)indole-3-carboxamide).

624 (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3-
625 carboxamide).

626 (V) Fluoro MN-18 (N-Naphthalen-1-yl 1-
627 (fluoropentyl)indazole-3-carboxamide).

628 m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl
629 indazole carboxamides, Alkylcarbonyl indole carboxylates, and
630 Alkylcarbonyl indazole carboxylates.—Any compound containing an
631 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,
632 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3-
633 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an
634 indole carboxamide, indazole carboxamide, indole carboxylate, or
635 indazole carboxylate, with or without substitution on the indole
636 or indazole ring to any extent, whether or not substituted on
637 the alkylcarbonyl group to any extent, including, but not
638 limited to:

639 (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
640 pentylindole-3-carboxamide).

641 (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-

19-00569-17

2017424__

642 yl)-1-(fluoropentyl)indole-3-carboxamide).

643 (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-

644 (fluoropentyl)indole-3-carboxamide).

645 (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-

646 pentylindazole-3-carboxamide).

647 (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-

648 1-(fluoropentyl)indazole-3-carboxamide).

649 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-

650 1-pentylindazole-3-carboxamide).

651 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-

652 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).

653 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-

654 (4-fluorobenzyl)indazole-3-carboxamide).

655 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-

656 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).

657 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-

658 (cyclohexylmethyl)indazole-3-carboxamide).

659 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-

660 (cyclohexylmethyl)indazole-3-carboxamide).

661 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-

662 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).

663 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-

664 pentylindazole-3-carboxamide).

665 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-

666 (fluoropentyl)indazole-3-carboxamide).

667 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4-

668 fluorobenzyl)indazole-3-carboxamide).

669 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-

670 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).

19-00569-17

2017424__

671 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-
672 2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).

673 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-
674 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).

675 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-
676 fluoropentyl)indole-3-carboxamide).

677 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-
678 fluoropentyl)indazole-3-carboxamide).

679 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-
680 (cyclohexylmethyl)indazole-3-carboxamide).

681 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4-
682 fluorobenzyl)indazole-3-carboxamide).

683 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-
684 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).

685 n. Cumylindolecarboxamides and Cumylindazolecarboxamides.-
686 Any compound containing a N-(2-phenylpropan-2-yl) indole
687 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide
688 structure, with or without substitution on the indole or
689 indazole ring to any extent, whether or not substituted on the
690 phenyl ring of the cumyl group to any extent, including, but not
691 limited to:

692 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3-
693 carboxamide).

694 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-
695 (fluoropentyl)indole-3-carboxamide).

696 o. Other Synthetic Cannabinoids.-Any material, compound,
697 mixture, or preparation that contains any quantity of a
698 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:

699 (I) With or without modification or replacement of a

19-00569-17

2017424__

700 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage
701 between either two core rings, or linkage between a core ring
702 and group structure, with or without the addition of a carbon or
703 replacement of a carbon;

704 (II) With or without replacement of a core ring or group
705 structure, whether or not substituted on the ring or group
706 structures to any extent; and

707 (III) Is a cannabinoid receptor agonist, unless
708 specifically excepted or unless listed in another schedule or
709 contained within a pharmaceutical product approved by the United
710 States Food and Drug Administration.

711 191. Substituted Cathinones.—Unless specifically excepted,
712 listed in another schedule, or contained within a pharmaceutical
713 product approved by the United States Food and Drug
714 Administration, any material, compound, mixture, or preparation,
715 including its salts, isomers, esters, or ethers, and salts of
716 isomers, esters, or ethers, whenever the existence of such salts
717 is possible within any of the following specific chemical
718 designations:

719 a. Any compound containing a 2-amino-1-phenyl-1-propanone
720 structure;

721 b. Any compound containing a 2-amino-1-naphthyl-1-propanone
722 structure; or

723 c. Any compound containing a 2-amino-1-thiophenyl-1-
724 propanone structure,
725 whether or not the compound is further modified:

726 (I) With or without substitution on the ring system to any
727 extent with alkyl, alkylthio, thio, fused alkylendioxy, alkoxy,
728 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused

19-00569-17

2017424__

729 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide
730 substituents;

731 (II) With or without substitution at the 3-propanone
732 position with an alkyl substituent or removal of the methyl
733 group at the 3-propanone position;

734 (III) With or without substitution at the 2-amino nitrogen
735 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or
736 not further substituted in the ring system; or

737 (IV) With or without inclusion of the 2-amino nitrogen atom
738 in a cyclic structure, including, but not limited to:

739 (A) Methcathinone.

740 (B) Ethcathinone.

741 (C) Methylone (3,4-Methylenedioxy-methcathinone).

742 (D) 2,3-Methylenedioxy-methcathinone.

743 (E) MDPV (3,4-Methylenedioxy-pyrovalerone).

744 (F) Methylenedioxy-methcathinone.

745 (G) Methoxy-methcathinone.

746 (H) Fluoro-methcathinone.

747 (I) Methyl-ethcathinone.

748 (J) Butylone (3,4-Methylenedioxy-alpha-
749 methylaminobutyrophenone).

750 (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).

751 (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).

752 (M) Naphyrone (Naphthylpyrovalerone).

753 (N) Bromo-methcathinone.

754 (O) Buphedrone (alpha-Methylaminobutyrophenone).

755 (P) Etylone (3,4-Methylenedioxy-alpha-
756 ethylaminobutyrophenone).

757 (Q) Dimethylcathinone.

19-00569-17

2017424__

758 (R) Dimethylmethcathinone.
759 (S) Pentylone (3,4-Methylenedioxy-alpha-
760 methylaminovalerophenone).
761 (T) Pentedrone (alpha-Methylaminovalerophenone).
762 (U) MDPDP (3,4-Methylenedioxy-alpha-
763 pyrrolidinopropiophenone).
764 (V) MDPBP (3,4-Methylenedioxy-alpha-
765 pyrrolidinobutyrophenone).
766 (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone).
767 (X) PPP (Pyrrolidinopropiophenone).
768 (Y) PVP (Pyrrolidinovalerophenone) or
769 (Pyrrolidinopentiophenone).
770 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
771 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).
772 (BB) F-MABP (Fluoromethylaminobutyrophenone).
773 (CC) Me-EABP (Methylethylaminobutyrophenone).
774 (DD) PBP (Pyrrolidinobutyrophenone).
775 (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone).
776 (FF) Et-PBP (Ethylpyrrolidinobutyrophenone).
777 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
778 (HH) Dimethylone (3,4-Methylenedioxy-N,N-
779 dimethylcathinone).
780 (II) 3,4-Methylenedioxy-N,N-diethylcathinone.
781 (JJ) 3,4-Methylenedioxy-N-acetylcathinone.
782 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.
783 (LL) 3,4-Methylenedioxy-N-acetylethcathinone.
784 (MM) Methylbuphedrone (Methyl-alpha-
785 methylaminobutyrophenone).
786 (NN) Methyl-alpha-methylaminohexanophenone.

19-00569-17

2017424__

- 787 (OO) N-Ethyl-N-methylcathinone.
- 788 (PP) PHP (Pyrrolidinohexanophenone).
- 789 (QQ) PV8 (Pyrrolidinoheptanophenone).
- 790 (RR) Chloromethcathinone.
- 791 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.
- 792 192. Substituted Phenethylamines.—Unless specifically
- 793 excepted or unless listed in another schedule, or contained
- 794 within a pharmaceutical product approved by the United States
- 795 Food and Drug Administration, any material, compound, mixture,
- 796 or preparation, including its salts, isomers, esters, or ethers,
- 797 and salts of isomers, esters, or ethers, whenever the existence
- 798 of such salts is possible within any of the following specific
- 799 chemical designations, any compound containing a phenethylamine
- 800 structure, without a beta-keto group, and without a benzyl group
- 801 attached to the amine group, whether or not the compound is
- 802 further modified with or without substitution on the phenyl ring
- 803 to any extent with alkyl, alkylthio, nitro, alkoxy, thio,
- 804 halide, fused alkylenedioxy, fused furan, fused benzofuran,
- 805 fused dihydrofuran, or fused tetrahydropyran substituents,
- 806 whether or not further substituted on a ring to any extent, with
- 807 or without substitution at the alpha or beta position by any
- 808 alkyl substituent, with or without substitution at the nitrogen
- 809 atom, and with or without inclusion of the 2-amino nitrogen atom
- 810 in a cyclic structure, including, but not limited to:
- 811 a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
- 812 b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
- 813 c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
- 814 d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
- 815 e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).

19-00569-17

2017424__

- 816 f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine) .
- 817 g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine) .
- 818 h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine) .
- 819 i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine) .
- 820 j. 2C-H (2,5-Dimethoxyphenethylamine) .
- 821 k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine) .
- 822 l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine) .
- 823 m. MDMA (3,4-Methylenedioxyamphetamine) .
- 824 n. MBDB (Methylbenzodioxolylbutanamine) or (3,4-
- 825 Methylenedioxy-N-methylbutanamine) .
- 826 o. MDA (3,4-Methylenedioxyamphetamine) .
- 827 p. 2,5-Dimethoxyamphetamine .
- 828 q. Fluoroamphetamine .
- 829 r. Fluoromethamphetamine .
- 830 s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine) .
- 831 t. DOB (4-Bromo-2,5-dimethoxyamphetamine) .
- 832 u. DOC (4-Chloro-2,5-dimethoxyamphetamine) .
- 833 v. DOET (4-Ethyl-2,5-dimethoxyamphetamine) .
- 834 w. DOI (4-Iodo-2,5-dimethoxyamphetamine) .
- 835 x. DOM (4-Methyl-2,5-dimethoxyamphetamine) .
- 836 y. PMA (4-Methoxyamphetamine) .
- 837 z. N-Ethylamphetamine .
- 838 aa. 3,4-Methylenedioxy-N-hydroxyamphetamine .
- 839 bb. 5-Methoxy-3,4-methylenedioxyamphetamine .
- 840 cc. PMMA (4-Methoxymethamphetamine) .
- 841 dd. N,N-Dimethylamphetamine .
- 842 ee. 3,4,5-Trimethoxyamphetamine .
- 843 ff. 4-APB (4-(2-Aminopropyl)benzofuran) .
- 844 gg. 5-APB (5-(2-Aminopropyl)benzofuran) .

19-00569-17

2017424__

- 845 hh. 6-APB (6-(2-Aminopropyl)benzofuran).
- 846 ii. 7-APB (7-(2-Aminopropyl)benzofuran).
- 847 jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 848 kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 849 ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 850 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 851 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).
- 852 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).
- 853 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).
- 854 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).
- 855 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).
- 856 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3-
- 857 dihydrobenzofuran),

858
 859 which does not include phenethylamine, mescaline as described in
 860 subparagraph 20., substituted cathinones as described in
 861 subparagraph 191., N-Benzyl phenethylamine compounds as
 862 described in subparagraph 193., or methamphetamine as described
 863 in subparagraph (2)(c)4.

864 193. N-Benzyl Phenethylamine Compounds.—Unless specifically
 865 excepted or unless listed in another schedule, or contained
 866 within a pharmaceutical product approved by the United States
 867 Food and Drug Administration, any material, compound, mixture,
 868 or preparation, including its salts, isomers, esters, or ethers,
 869 and salts of isomers, esters, or ethers, whenever the existence
 870 of such salts is possible within any of the following specific
 871 chemical designations, any compound containing a phenethylamine
 872 structure without a beta-keto group, with substitution on the
 873 nitrogen atom of the amino group with a benzyl substituent, with

19-00569-17

2017424__

874 or without substitution on the phenyl or benzyl ring to any
875 extent with alkyl, alkoxy, thio, alkylthio, halide, fused
876 alkylenedioxy, fused furan, fused benzofuran, or fused
877 tetrahydropyran substituents, whether or not further substituted
878 on a ring to any extent, with or without substitution at the
879 alpha position by any alkyl substituent, including, but not
880 limited to:

881 a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-
882 methoxybenzyl)]phenethylamine).

883 b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2-
884 hydroxybenzyl)]phenethylamine).

885 c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2-
886 fluorobenzyl)]phenethylamine).

887 d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3-
888 methylenedioxybenzyl)]phenethylamine).

889 e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-
890 methoxybenzyl)]phenethylamine).

891 f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2-
892 hydroxybenzyl)]phenethylamine).

893 g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2-
894 fluorobenzyl)]phenethylamine).

895 h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3-
896 methylenedioxybenzyl)]phenethylamine).

897 i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2-
898 methoxybenzyl)]phenethylamine).

899 j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2-
900 methoxybenzyl)]phenethylamine).

901 k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2-
902 methoxybenzyl)]phenethylamine).

19-00569-17

2017424__

903 1. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-
904 methoxybenzyl)]phenethylamine).

905 m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2-
906 hydroxybenzyl)]phenethylamine).

907 n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2-
908 fluorobenzyl)]phenethylamine).

909 o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3-
910 methylenedioxybenzyl)]phenethylamine).

911 p. 25H-NBOMe (2,5-Dimethoxy-[N-(2-
912 methoxybenzyl)]phenethylamine).

913 q. 25H-NBOH (2,5-Dimethoxy-[N-(2-
914 hydroxybenzyl)]phenethylamine).

915 r. 25H-NBF (2,5-Dimethoxy-[N-(2-
916 fluorobenzyl)]phenethylamine).

917 s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2-
918 methoxybenzyl)]phenethylamine),

919

920 which does not include substituted cathinones as described in
921 subparagraph 191.

922 194. Substituted Tryptamines.—Unless specifically excepted
923 or unless listed in another schedule, or contained within a
924 pharmaceutical product approved by the United States Food and
925 Drug Administration, any material, compound, mixture, or
926 preparation containing a 2-(1H-indol-3-yl)ethanamine, for
927 example tryptamine, structure with or without mono- or di-
928 substitution of the amine nitrogen with alkyl or alkenyl groups,
929 or by inclusion of the amino nitrogen atom in a cyclic
930 structure, whether or not substituted at the alpha position with
931 an alkyl group, whether or not substituted on the indole ring to

19-00569-17

2017424__

- 932 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy
933 groups, including, but not limited to:
- 934 a. Alpha-Ethyltryptamine.
 - 935 b. Bufotenine.
 - 936 c. DET (Diethyltryptamine).
 - 937 d. DMT (Dimethyltryptamine).
 - 938 e. MET (N-Methyl-N-ethyltryptamine).
 - 939 f. DALT (N,N-Diallyltryptamine).
 - 940 g. EiPT (N-Ethyl-N-isopropyltryptamine).
 - 941 h. MiPT (N-Methyl-N-isopropyltryptamine).
 - 942 i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
 - 943 j. 5-Hydroxy-N-methyltryptamine.
 - 944 k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
 - 945 l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
 - 946 m. Methyltryptamine.
 - 947 n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
 - 948 o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
 - 949 p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
 - 950 q. DiPT (N,N-Diisopropyltryptamine).
 - 951 r. DPT (N,N-Dipropyltryptamine).
 - 952 s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
 - 953 t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
 - 954 u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).
 - 955 v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).
 - 956 w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).
 - 957 x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).
 - 958 y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N-
959 isopropyltryptamine).
 - 960 z. Methyl-alpha-ethyltryptamine.

19-00569-17

2017424__

- 961 aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),
962
963 which does not include tryptamine, psilocyn as described in
964 subparagraph 34., or psilocybin as described in subparagraph 33.
965 195. Substituted Phenylcyclohexylamines.—Unless
966 specifically excepted or unless listed in another schedule, or
967 contained within a pharmaceutical product approved by the United
968 States Food and Drug Administration, any material, compound,
969 mixture, or preparation containing a phenylcyclohexylamine
970 structure, with or without any substitution on the phenyl ring,
971 any substitution on the cyclohexyl ring, any replacement of the
972 phenyl ring with a thiophenyl or benzothiophenyl ring, with or
973 without substitution on the amine with alkyl, dialkyl, or alkoxy
974 substituents, inclusion of the nitrogen in a cyclic structure,
975 or any combination of the above, including, but not limited to:
- 976 a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
977 (Benocyclidine).
 - 978 b. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine analog
979 of phencyclidine).
 - 980 c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
981 analog of phencyclidine).
 - 982 d. PCPr (Phenylcyclohexylpropylamine).
 - 983 e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine) (Thiophene
984 analog of phencyclidine).
 - 985 f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)).
 - 986 g. PCMPA (Phenylcyclohexyl(methoxypropylamine)).
 - 987 h. Methoxetamine.
 - 988 i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
 - 989 j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).

19-00569-17

2017424__

- 990 k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
- 991 l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).
- 992 m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
- 993 n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
- 994 o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).
- 995 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
- 996 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
- 997 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).

998 196. Mitragynine or 7-Hydroxymitragynine, except for any
 999 drug product approved by the United States Food and Drug
 1000 Administration which contains Mitragynine or 7-
 1001 Hydroxymitragynine, including any of their isomers, esters,
 1002 ethers, salts, and salts of isomers, esters, and ethers, if the
 1003 existence of such isomers, esters, ethers, and salts is possible
 1004 within the specific chemical designation.

1005 Section 2. Subsection (11) is added to section 893.13,
 1006 Florida Statutes, to read:

1007 893.13 Prohibited acts; penalties.—

1008 (11) Any prohibited act related to the controlled substance
 1009 described in s. 893.03(1)(c)196. shall be exclusively governed
 1010 by this subsection. A person who sells, delivers, manufactures,
 1011 or brings into this state, or possesses with intent to sell,
 1012 deliver, manufacture, or bring into this state, the controlled
 1013 substance described in s. 893.03(1)(c)196. commits a misdemeanor
 1014 of the first degree, punishable as provided in s. 775.082 or s.
 1015 775.083.

1016 Section 3. For the purpose of incorporating the amendment
 1017 made by this act to section 893.03, Florida Statutes, in
 1018 references thereto, paragraphs (a) and (g) of subsection (30) of

19-00569-17

2017424__

1019 section 39.01, Florida Statutes, are reenacted to read:

1020 39.01 Definitions.—When used in this chapter, unless the
1021 context otherwise requires:

1022 (30) "Harm" to a child's health or welfare can occur when
1023 any person:

1024 (a) Inflicts or allows to be inflicted upon the child
1025 physical, mental, or emotional injury. In determining whether
1026 harm has occurred, the following factors must be considered in
1027 evaluating any physical, mental, or emotional injury to a child:
1028 the age of the child; any prior history of injuries to the
1029 child; the location of the injury on the body of the child; the
1030 multiplicity of the injury; and the type of trauma inflicted.

1031 Such injury includes, but is not limited to:

1032 1. Willful acts that produce the following specific
1033 injuries:

- 1034 a. Sprains, dislocations, or cartilage damage.
1035 b. Bone or skull fractures.
1036 c. Brain or spinal cord damage.
1037 d. Intracranial hemorrhage or injury to other internal
1038 organs.
1039 e. Asphyxiation, suffocation, or drowning.
1040 f. Injury resulting from the use of a deadly weapon.
1041 g. Burns or scalding.
1042 h. Cuts, lacerations, punctures, or bites.
1043 i. Permanent or temporary disfigurement.
1044 j. Permanent or temporary loss or impairment of a body part
1045 or function.

1046
1047 As used in this subparagraph, the term "willful" refers to the

19-00569-17

2017424__

1048 intent to perform an action, not to the intent to achieve a
1049 result or to cause an injury.

1050 2. Purposely giving a child poison, alcohol, drugs, or
1051 other substances that substantially affect the child's behavior,
1052 motor coordination, or judgment or that result in sickness or
1053 internal injury. For the purposes of this subparagraph, the term
1054 "drugs" means prescription drugs not prescribed for the child or
1055 not administered as prescribed, and controlled substances as
1056 outlined in Schedule I or Schedule II of s. 893.03.

1057 3. Leaving a child without adult supervision or arrangement
1058 appropriate for the child's age or mental or physical condition,
1059 so that the child is unable to care for the child's own needs or
1060 another's basic needs or is unable to exercise good judgment in
1061 responding to any kind of physical or emotional crisis.

1062 4. Inappropriate or excessively harsh disciplinary action
1063 that is likely to result in physical injury, mental injury as
1064 defined in this section, or emotional injury. The significance
1065 of any injury must be evaluated in light of the following
1066 factors: the age of the child; any prior history of injuries to
1067 the child; the location of the injury on the body of the child;
1068 the multiplicity of the injury; and the type of trauma
1069 inflicted. Corporal discipline may be considered excessive or
1070 abusive when it results in any of the following or other similar
1071 injuries:

- 1072 a. Sprains, dislocations, or cartilage damage.
- 1073 b. Bone or skull fractures.
- 1074 c. Brain or spinal cord damage.
- 1075 d. Intracranial hemorrhage or injury to other internal
1076 organs.

19-00569-17

2017424__

- 1077 e. Asphyxiation, suffocation, or drowning.
- 1078 f. Injury resulting from the use of a deadly weapon.
- 1079 g. Burns or scalding.
- 1080 h. Cuts, lacerations, punctures, or bites.
- 1081 i. Permanent or temporary disfigurement.
- 1082 j. Permanent or temporary loss or impairment of a body part
- 1083 or function.

1084 k. Significant bruises or welts.

1085 (g) Exposes a child to a controlled substance or alcohol.

1086 Exposure to a controlled substance or alcohol is established by:

1087 1. A test, administered at birth, which indicated that the

1088 child's blood, urine, or meconium contained any amount of

1089 alcohol or a controlled substance or metabolites of such

1090 substances, the presence of which was not the result of medical

1091 treatment administered to the mother or the newborn infant; or

1092 2. Evidence of extensive, abusive, and chronic use of a

1093 controlled substance or alcohol by a parent when the child is

1094 demonstrably adversely affected by such usage.

1095

1096 As used in this paragraph, the term "controlled substance" means

1097 prescription drugs not prescribed for the parent or not

1098 administered as prescribed and controlled substances as outlined

1099 in Schedule I or Schedule II of s. 893.03.

1100 Section 4. For the purpose of incorporating the amendment

1101 made by this act to section 893.03, Florida Statutes, in a

1102 reference thereto, subsection (5) of section 316.193, Florida

1103 Statutes, is reenacted to read:

1104 316.193 Driving under the influence; penalties.-

1105 (5) The court shall place all offenders convicted of

19-00569-17

2017424__

1106 violating this section on monthly reporting probation and shall
1107 require completion of a substance abuse course conducted by a
1108 DUI program licensed by the department under s. 322.292, which
1109 must include a psychosocial evaluation of the offender. If the
1110 DUI program refers the offender to an authorized substance abuse
1111 treatment provider for substance abuse treatment, in addition to
1112 any sentence or fine imposed under this section, completion of
1113 all such education, evaluation, and treatment is a condition of
1114 reporting probation. The offender shall assume reasonable costs
1115 for such education, evaluation, and treatment. The referral to
1116 treatment resulting from a psychosocial evaluation shall not be
1117 waived without a supporting independent psychosocial evaluation
1118 conducted by an authorized substance abuse treatment provider
1119 appointed by the court, which shall have access to the DUI
1120 program's psychosocial evaluation before the independent
1121 psychosocial evaluation is conducted. The court shall review the
1122 results and recommendations of both evaluations before
1123 determining the request for waiver. The offender shall bear the
1124 full cost of this procedure. The term "substance abuse" means
1125 the abuse of alcohol or any substance named or described in
1126 Schedules I through V of s. 893.03. If an offender referred to
1127 treatment under this subsection fails to report for or complete
1128 such treatment or fails to complete the DUI program substance
1129 abuse education course and evaluation, the DUI program shall
1130 notify the court and the department of the failure. Upon receipt
1131 of the notice, the department shall cancel the offender's
1132 driving privilege, notwithstanding the terms of the court order
1133 or any suspension or revocation of the driving privilege. The
1134 department may temporarily reinstate the driving privilege on a

19-00569-17

2017424__

1135 restricted basis upon verification from the DUI program that the
1136 offender is currently participating in treatment and the DUI
1137 education course and evaluation requirement has been completed.
1138 If the DUI program notifies the department of the second failure
1139 to complete treatment, the department shall reinstate the
1140 driving privilege only after notice of completion of treatment
1141 from the DUI program. The organization that conducts the
1142 substance abuse education and evaluation may not provide
1143 required substance abuse treatment unless a waiver has been
1144 granted to that organization by the department. A waiver may be
1145 granted only if the department determines, in accordance with
1146 its rules, that the service provider that conducts the substance
1147 abuse education and evaluation is the most appropriate service
1148 provider and is licensed under chapter 397 or is exempt from
1149 such licensure. A statistical referral report shall be submitted
1150 quarterly to the department by each organization authorized to
1151 provide services under this section.

1152 Section 5. For the purpose of incorporating the amendment
1153 made by this act to section 893.03, Florida Statutes, in a
1154 reference thereto, paragraph (c) of subsection (2) of section
1155 322.2616, Florida Statutes, is reenacted to read:

1156 322.2616 Suspension of license; persons under 21 years of
1157 age; right to review.—

1158 (2)

1159 (c) When a driver subject to this section has a blood-
1160 alcohol or breath-alcohol level of 0.05 or higher, the
1161 suspension shall remain in effect until such time as the driver
1162 has completed a substance abuse course offered by a DUI program
1163 licensed by the department. The driver shall assume the

19-00569-17

2017424__

1164 reasonable costs for the substance abuse course. As part of the
1165 substance abuse course, the program shall conduct a substance
1166 abuse evaluation of the driver, and notify the parents or legal
1167 guardians of drivers under the age of 19 years of the results of
1168 the evaluation. The term "substance abuse" means the abuse of
1169 alcohol or any substance named or described in Schedules I
1170 through V of s. 893.03. If a driver fails to complete the
1171 substance abuse education course and evaluation, the driver
1172 license shall not be reinstated by the department.

1173 Section 6. For the purpose of incorporating the amendment
1174 made by this act to section 893.03, Florida Statutes, in a
1175 reference thereto, subsection (5) of section 327.35, Florida
1176 Statutes, is reenacted to read:

1177 327.35 Boating under the influence; penalties; "designated
1178 drivers."—

1179 (5) In addition to any sentence or fine, the court shall
1180 place any offender convicted of violating this section on
1181 monthly reporting probation and shall require attendance at a
1182 substance abuse course specified by the court; and the agency
1183 conducting the course may refer the offender to an authorized
1184 service provider for substance abuse evaluation and treatment,
1185 in addition to any sentence or fine imposed under this section.
1186 The offender shall assume reasonable costs for such education,
1187 evaluation, and treatment, with completion of all such
1188 education, evaluation, and treatment being a condition of
1189 reporting probation. Treatment resulting from a psychosocial
1190 evaluation may not be waived without a supporting psychosocial
1191 evaluation conducted by an agency appointed by the court and
1192 with access to the original evaluation. The offender shall bear

19-00569-17

2017424__

1193 the cost of this procedure. The term "substance abuse" means the
1194 abuse of alcohol or any substance named or described in
1195 Schedules I-V of s. 893.03.

1196 Section 7. For the purpose of incorporating the amendment
1197 made by this act to section 893.03, Florida Statutes, in a
1198 reference thereto, paragraph (b) of subsection (11) of section
1199 440.102, Florida Statutes, is reenacted to read:

1200 440.102 Drug-free workplace program requirements.—The
1201 following provisions apply to a drug-free workplace program
1202 implemented pursuant to law or to rules adopted by the Agency
1203 for Health Care Administration:

1204 (11) PUBLIC EMPLOYEES IN MANDATORY-TESTING OR SPECIAL-RISK
1205 POSITIONS.—

1206 (b) An employee who is employed by a public employer in a
1207 special-risk position may be discharged or disciplined by a
1208 public employer for the first positive confirmed test result if
1209 the drug confirmed is an illicit drug under s. 893.03. A
1210 special-risk employee who is participating in an employee
1211 assistance program or drug rehabilitation program may not be
1212 allowed to continue to work in any special-risk or mandatory-
1213 testing position of the public employer, but may be assigned to
1214 a position other than a mandatory-testing position or placed on
1215 leave while the employee is participating in the program.
1216 However, the employee shall be permitted to use any accumulated
1217 annual leave credits before leave may be ordered without pay.

1218 Section 8. For the purpose of incorporating the amendment
1219 made by this act to section 893.03, Florida Statutes, in a
1220 reference thereto, paragraph (e) of subsection (1) of section
1221 458.3265, Florida Statutes, is reenacted to read:

19-00569-17

2017424__

1222 458.3265 Pain-management clinics.-

1223 (1) REGISTRATION.-

1224 (e) The department shall deny registration to any pain-
1225 management clinic owned by or with any contractual or employment
1226 relationship with a physician:

1227 1. Whose Drug Enforcement Administration number has ever
1228 been revoked.

1229 2. Whose application for a license to prescribe, dispense,
1230 or administer a controlled substance has been denied by any
1231 jurisdiction.

1232 3. Who has been convicted of or pleaded guilty or nolo
1233 contendere to, regardless of adjudication, an offense that
1234 constitutes a felony for receipt of illicit and diverted drugs,
1235 including a controlled substance listed in Schedule I, Schedule
1236 II, Schedule III, Schedule IV, or Schedule V of s. 893.03, in
1237 this state, any other state, or the United States.

1238 Section 9. For the purpose of incorporating the amendment
1239 made by this act to section 893.03, Florida Statutes, in a
1240 reference thereto, paragraph (e) of subsection (1) of section
1241 459.0137, Florida Statutes, is reenacted to read:

1242 459.0137 Pain-management clinics.-

1243 (1) REGISTRATION.-

1244 (e) The department shall deny registration to any pain-
1245 management clinic owned by or with any contractual or employment
1246 relationship with a physician:

1247 1. Whose Drug Enforcement Administration number has ever
1248 been revoked.

1249 2. Whose application for a license to prescribe, dispense,
1250 or administer a controlled substance has been denied by any

19-00569-17

2017424__

1251 jurisdiction.

1252 3. Who has been convicted of or pleaded guilty or nolo
1253 contendere to, regardless of adjudication, an offense that
1254 constitutes a felony for receipt of illicit and diverted drugs,
1255 including a controlled substance listed in Schedule I, Schedule
1256 II, Schedule III, Schedule IV, or Schedule V of s. 893.03, in
1257 this state, any other state, or the United States.

1258 Section 10. For the purpose of incorporating the amendment
1259 made by this act to section 893.03, Florida Statutes, in
1260 references thereto, paragraph (a) of subsection (1) and
1261 subsection (4) of section 782.04, Florida Statutes, are
1262 reenacted to read:

1263 782.04 Murder.—

1264 (1) (a) The unlawful killing of a human being:

1265 1. When perpetrated from a premeditated design to effect
1266 the death of the person killed or any human being;

1267 2. When committed by a person engaged in the perpetration
1268 of, or in the attempt to perpetrate, any:

1269 a. Trafficking offense prohibited by s. 893.135(1),

1270 b. Arson,

1271 c. Sexual battery,

1272 d. Robbery,

1273 e. Burglary,

1274 f. Kidnapping,

1275 g. Escape,

1276 h. Aggravated child abuse,

1277 i. Aggravated abuse of an elderly person or disabled adult,

1278 j. Aircraft piracy,

1279 k. Unlawful throwing, placing, or discharging of a

19-00569-17

2017424__

1280 destructive device or bomb,
1281 1. Carjacking,
1282 m. Home-invasion robbery,
1283 n. Aggravated stalking,
1284 o. Murder of another human being,
1285 p. Resisting an officer with violence to his or her person,
1286 q. Aggravated fleeing or eluding with serious bodily injury
1287 or death,
1288 r. Felony that is an act of terrorism or is in furtherance
1289 of an act of terrorism,
1290 s. Human trafficking; or
1291 3. Which resulted from the unlawful distribution of any
1292 substance controlled under s. 893.03(1), cocaine as described in
1293 s. 893.03(2)(a)4., opium or any synthetic or natural salt,
1294 compound, derivative, or preparation of opium, or methadone by a
1295 person 18 years of age or older, when such drug is proven to be
1296 the proximate cause of the death of the user,
1297
1298 is murder in the first degree and constitutes a capital felony,
1299 punishable as provided in s. 775.082.
1300 (4) The unlawful killing of a human being, when perpetrated
1301 without any design to effect death, by a person engaged in the
1302 perpetration of, or in the attempt to perpetrate, any felony
1303 other than any:
1304 (a) Trafficking offense prohibited by s. 893.135(1),
1305 (b) Arson,
1306 (c) Sexual battery,
1307 (d) Robbery,
1308 (e) Burglary,

19-00569-17

2017424__

1309 (f) Kidnapping,
 1310 (g) Escape,
 1311 (h) Aggravated child abuse,
 1312 (i) Aggravated abuse of an elderly person or disabled
 1313 adult,
 1314 (j) Aircraft piracy,
 1315 (k) Unlawful throwing, placing, or discharging of a
 1316 destructive device or bomb,
 1317 (l) Unlawful distribution of any substance controlled under
 1318 s. 893.03(1), cocaine as described in s. 893.03(2)(a)4., or
 1319 opium or any synthetic or natural salt, compound, derivative, or
 1320 preparation of opium by a person 18 years of age or older, when
 1321 such drug is proven to be the proximate cause of the death of
 1322 the user,
 1323 (m) Carjacking,
 1324 (n) Home-invasion robbery,
 1325 (o) Aggravated stalking,
 1326 (p) Murder of another human being,
 1327 (q) Aggravated fleeing or eluding with serious bodily
 1328 injury or death,
 1329 (r) Resisting an officer with violence to his or her
 1330 person, or
 1331 (s) Felony that is an act of terrorism or is in furtherance
 1332 of an act of terrorism,
 1333
 1334 is murder in the third degree and constitutes a felony of the
 1335 second degree, punishable as provided in s. 775.082, s. 775.083,
 1336 or s. 775.084.
 1337 Section 11. For the purpose of incorporating the amendment

19-00569-17

2017424__

1338 made by this act to section 893.03, Florida Statutes, in a
1339 reference thereto, paragraph (a) of subsection (2) of section
1340 787.06, Florida Statutes, is reenacted to read:

1341 787.06 Human trafficking.—

1342 (2) As used in this section, the term:

1343 (a) "Coercion" means:

1344 1. Using or threatening to use physical force against any
1345 person;

1346 2. Restraining, isolating, or confining or threatening to
1347 restrain, isolate, or confine any person without lawful
1348 authority and against her or his will;

1349 3. Using lending or other credit methods to establish a
1350 debt by any person when labor or services are pledged as a
1351 security for the debt, if the value of the labor or services as
1352 reasonably assessed is not applied toward the liquidation of the
1353 debt, the length and nature of the labor or services are not
1354 respectively limited and defined;

1355 4. Destroying, concealing, removing, confiscating,
1356 withholding, or possessing any actual or purported passport,
1357 visa, or other immigration document, or any other actual or
1358 purported government identification document, of any person;

1359 5. Causing or threatening to cause financial harm to any
1360 person;

1361 6. Enticing or luring any person by fraud or deceit; or

1362 7. Providing a controlled substance as outlined in Schedule
1363 I or Schedule II of s. 893.03 to any person for the purpose of
1364 exploitation of that person.

1365 Section 12. For the purpose of incorporating the amendment
1366 made by this act to section 893.03, Florida Statutes, in a

19-00569-17

2017424__

1367 reference thereto, section 817.563, Florida Statutes, is
1368 reenacted to read:

1369 817.563 Controlled substance named or described in s.
1370 893.03; sale of substance in lieu thereof.—It is unlawful for
1371 any person to agree, consent, or in any manner offer to
1372 unlawfully sell to any person a controlled substance named or
1373 described in s. 893.03 and then sell to such person any other
1374 substance in lieu of such controlled substance. Any person who
1375 violates this section with respect to:

1376 (1) A controlled substance named or described in s.
1377 893.03(1), (2), (3), or (4) is guilty of a felony of the third
1378 degree, punishable as provided in s. 775.082, s. 775.083, or s.
1379 775.084.

1380 (2) A controlled substance named or described in s.
1381 893.03(5) is guilty of a misdemeanor of the second degree,
1382 punishable as provided in s. 775.082 or s. 775.083.

1383 Section 13. For the purpose of incorporating the amendment
1384 made by this act to section 893.03, Florida Statutes, in
1385 references thereto, paragraph (a) of subsection (1) and
1386 subsection (2) of section 831.31, Florida Statutes, are
1387 reenacted to read:

1388 831.31 Counterfeit controlled substance; sale, manufacture,
1389 delivery, or possession with intent to sell, manufacture, or
1390 deliver.—

1391 (1) It is unlawful for any person to sell, manufacture, or
1392 deliver, or to possess with intent to sell, manufacture, or
1393 deliver, a counterfeit controlled substance. Any person who
1394 violates this subsection with respect to:

1395 (a) A controlled substance named or described in s.

19-00569-17

2017424__

1396 893.03(1), (2), (3), or (4) is guilty of a felony of the third
1397 degree, punishable as provided in s. 775.082, s. 775.083, or s.
1398 775.084.

1399 (2) For purposes of this section, "counterfeit controlled
1400 substance" means:

1401 (a) A controlled substance named or described in s. 893.03
1402 which, or the container or labeling of which, without
1403 authorization bears the trademark, trade name, or other
1404 identifying mark, imprint, or number, or any likeness thereof,
1405 of a manufacturer other than the person who in fact manufactured
1406 the controlled substance; or

1407 (b) Any substance which is falsely identified as a
1408 controlled substance named or described in s. 893.03.

1409 Section 14. For the purpose of incorporating the amendment
1410 made by this act to section 893.03, Florida Statutes, in a
1411 reference thereto, paragraph (c) of subsection (1) of section
1412 856.015, Florida Statutes, is reenacted to read:

1413 856.015 Open house parties.—

1414 (1) Definitions.—As used in this section:

1415 (c) "Drug" means a controlled substance, as that term is
1416 defined in ss. 893.02(4) and 893.03.

1417 Section 15. For the purpose of incorporating the amendment
1418 made by this act to section 893.03, Florida Statutes, in a
1419 reference thereto, subsection (4) of section 893.02, Florida
1420 Statutes, is reenacted to read:

1421 893.02 Definitions.—The following words and phrases as used
1422 in this chapter shall have the following meanings, unless the
1423 context otherwise requires:

1424 (4) "Controlled substance" means any substance named or

19-00569-17

2017424__

1425 described in Schedules I-V of s. 893.03. Laws controlling the
1426 manufacture, distribution, preparation, dispensing, or
1427 administration of such substances are drug abuse laws.

1428 Section 16. For the purpose of incorporating the amendment
1429 made by this act to section 893.03, Florida Statutes, in
1430 references thereto, subsection (2), paragraph (a) of subsection
1431 (7), and paragraph (a) of subsection (8) of section 893.035,
1432 Florida Statutes, are reenacted to read:

1433 893.035 Control of new substances; findings of fact;
1434 delegation of authority to Attorney General to control
1435 substances by rule.—

1436 (2) The Attorney General shall apply the provisions of this
1437 section to any substance not currently controlled under the
1438 provisions of s. 893.03. The Attorney General may by rule:

1439 (a) Add a substance to a schedule established by s. 893.03,
1440 or transfer a substance between schedules, if he or she finds
1441 that it has a potential for abuse and he or she makes with
1442 respect to it the other findings appropriate for classification
1443 in the particular schedule under s. 893.03 in which it is to be
1444 placed.

1445 (b) Remove a substance previously added to a schedule if he
1446 or she finds the substance does not meet the requirements for
1447 inclusion in that schedule.

1448
1449 Rules adopted under this section shall be made pursuant to the
1450 rulemaking procedures prescribed by chapter 120.

1451 (7) (a) If the Attorney General finds that the scheduling of
1452 a substance in Schedule I of s. 893.03 on a temporary basis is
1453 necessary to avoid an imminent hazard to the public safety, he

19-00569-17

2017424__

1454 or she may by rule and without regard to the requirements of
1455 subsection (5) relating to the Department of Health and the
1456 Department of Law Enforcement schedule such substance in
1457 Schedule I if the substance is not listed in any other schedule
1458 of s. 893.03. The Attorney General shall be required to
1459 consider, with respect to his or her finding of imminent hazard
1460 to the public safety, only those factors set forth in paragraphs
1461 (3) (a) and (4) (d), (e), and (f), including actual abuse,
1462 diversion from legitimate channels, and clandestine importation,
1463 manufacture, or distribution.

1464 (8) (a) Upon the effective date of a rule adopted pursuant
1465 to this section adding or transferring a substance to a schedule
1466 under s. 893.03, such substance shall be deemed included in that
1467 schedule, and all provisions of this chapter applicable to
1468 substances in that schedule shall be deemed applicable to such
1469 substance.

1470 Section 17. For the purpose of incorporating the amendment
1471 made by this act to section 893.03, Florida Statutes, in
1472 references thereto, paragraph (a) of subsection (2) and
1473 subsection (5) of section 893.0356, Florida Statutes, are
1474 reenacted to read:

1475 893.0356 Control of new substances; findings of fact;
1476 "controlled substance analog" defined.—

1477 (2) (a) As used in this section, "controlled substance
1478 analog" means a substance which, due to its chemical structure
1479 and potential for abuse, meets the following criteria:

- 1480 1. Is substantially similar to that of a controlled
1481 substance listed in Schedule I or Schedule II of s. 893.03; and
- 1482 2. Has a stimulant, depressant, or hallucinogenic effect on

19-00569-17

2017424__

1483 the central nervous system or is represented or intended to have
1484 a stimulant, depressant, or hallucinogenic effect on the central
1485 nervous system substantially similar to or greater than that of
1486 a controlled substance listed in Schedule I or Schedule II of s.
1487 893.03.

1488 (5) A controlled substance analog shall, for purposes of
1489 drug abuse prevention and control, be treated as the highest
1490 scheduled controlled substance of which it is a controlled
1491 substance analog in s. 893.03.

1492 Section 18. For the purpose of incorporating the amendment
1493 made by this act to section 893.03, Florida Statutes, in a
1494 reference thereto, paragraph (d) of subsection (1) of section
1495 893.05, Florida Statutes, is reenacted to read:

1496 893.05 Practitioners and persons administering controlled
1497 substances in their absence.—

1498 (1)

1499 (d) A certified optometrist licensed under chapter 463 may
1500 not administer or prescribe a controlled substance listed in
1501 Schedule I or Schedule II of s. 893.03.

1502 Section 19. For the purpose of incorporating the amendment
1503 made by this act to section 893.03, Florida Statutes, in
1504 references thereto, paragraphs (b), (c), and (d) of subsection
1505 (2) of section 893.12, Florida Statutes, are reenacted to read:

1506 893.12 Contraband; seizure, forfeiture, sale.—

1507 (2)

1508 (b) All real property, including any right, title,
1509 leasehold interest, and other interest in the whole of any lot
1510 or tract of land and any appurtenances or improvements, which
1511 real property is used, or intended to be used, in any manner or

19-00569-17

2017424__

1512 part, to commit or to facilitate the commission of, or which
1513 real property is acquired with proceeds obtained as a result of,
1514 a violation of any provision of this chapter related to a
1515 controlled substance described in s. 893.03(1) or (2) may be
1516 seized and forfeited as provided by the Florida Contraband
1517 Forfeiture Act except that no property shall be forfeited under
1518 this paragraph to the extent of an interest of an owner or
1519 lienholder by reason of any act or omission established by that
1520 owner or lienholder to have been committed or omitted without
1521 the knowledge or consent of that owner or lienholder.

1522 (c) All moneys, negotiable instruments, securities, and
1523 other things of value furnished or intended to be furnished by
1524 any person in exchange for a controlled substance described in
1525 s. 893.03(1) or (2) or a listed chemical in violation of any
1526 provision of this chapter, all proceeds traceable to such an
1527 exchange, and all moneys, negotiable instruments, and securities
1528 used or intended to be used to facilitate any violation of any
1529 provision of this chapter or which are acquired with proceeds
1530 obtained in violation of any provision of this chapter may be
1531 seized and forfeited as provided by the Florida Contraband
1532 Forfeiture Act, except that no property shall be forfeited under
1533 this paragraph to the extent of an interest of an owner or
1534 lienholder by reason of any act or omission established by that
1535 owner or lienholder to have been committed or omitted without
1536 the knowledge or consent of that owner or lienholder.

1537 (d) All books, records, and research, including formulas,
1538 microfilm, tapes, and data which are used, or intended for use,
1539 or which are acquired with proceeds obtained, in violation of
1540 any provision of this chapter related to a controlled substance

19-00569-17

2017424__

1541 described in s. 893.03(1) or (2) or a listed chemical may be
1542 seized and forfeited as provided by the Florida Contraband
1543 Forfeiture Act.

1544 Section 20. For the purpose of incorporating the amendment
1545 made by this act to section 893.03, Florida Statutes, in
1546 references thereto, paragraphs (a), (c), (d), (e), (f), and (h)
1547 of subsection (1), paragraph (a) of subsection (2), paragraph
1548 (b) of subsection (4), paragraph (b) of subsection (5), and
1549 paragraph (a) of subsection (7) of section 893.13, Florida
1550 Statutes, are reenacted to read:

1551 893.13 Prohibited acts; penalties.—

1552 (1) (a) Except as authorized by this chapter and chapter
1553 499, a person may not sell, manufacture, or deliver, or possess
1554 with intent to sell, manufacture, or deliver, a controlled
1555 substance. A person who violates this provision with respect to:

1556 1. A controlled substance named or described in s.
1557 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c) 4.
1558 commits a felony of the second degree, punishable as provided in
1559 s. 775.082, s. 775.083, or s. 775.084.

1560 2. A controlled substance named or described in s.
1561 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
1562 (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
1563 the third degree, punishable as provided in s. 775.082, s.
1564 775.083, or s. 775.084.

1565 3. A controlled substance named or described in s.
1566 893.03(5) commits a misdemeanor of the first degree, punishable
1567 as provided in s. 775.082 or s. 775.083.

1568 (c) Except as authorized by this chapter, a person may not
1569 sell, manufacture, or deliver, or possess with intent to sell,

19-00569-17

2017424__

1570 manufacture, or deliver, a controlled substance in, on, or
1571 within 1,000 feet of the real property comprising a child care
1572 facility as defined in s. 402.302 or a public or private
1573 elementary, middle, or secondary school between the hours of 6
1574 a.m. and 12 midnight, or at any time in, on, or within 1,000
1575 feet of real property comprising a state, county, or municipal
1576 park, a community center, or a publicly owned recreational
1577 facility. As used in this paragraph, the term "community center"
1578 means a facility operated by a nonprofit community-based
1579 organization for the provision of recreational, social, or
1580 educational services to the public. A person who violates this
1581 paragraph with respect to:

1582 1. A controlled substance named or described in s.
1583 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
1584 commits a felony of the first degree, punishable as provided in
1585 s. 775.082, s. 775.083, or s. 775.084. The defendant must be
1586 sentenced to a minimum term of imprisonment of 3 calendar years
1587 unless the offense was committed within 1,000 feet of the real
1588 property comprising a child care facility as defined in s.
1589 402.302.

1590 2. A controlled substance named or described in s.
1591 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
1592 (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
1593 the second degree, punishable as provided in s. 775.082, s.
1594 775.083, or s. 775.084.

1595 3. Any other controlled substance, except as lawfully sold,
1596 manufactured, or delivered, must be sentenced to pay a \$500 fine
1597 and to serve 100 hours of public service in addition to any
1598 other penalty prescribed by law.

19-00569-17

2017424__

1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627

This paragraph does not apply to a child care facility unless the owner or operator of the facility posts a sign that is not less than 2 square feet in size with a word legend identifying the facility as a licensed child care facility and that is posted on the property of the child care facility in a conspicuous place where the sign is reasonably visible to the public.

(d) Except as authorized by this chapter, a person may not sell, manufacture, or deliver, or possess with intent to sell, manufacture, or deliver, a controlled substance in, on, or within 1,000 feet of the real property comprising a public or private college, university, or other postsecondary educational institution. A person who violates this paragraph with respect to:

1. A controlled substance named or described in s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4. commits a felony of the first degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084.

2. A controlled substance named or described in s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of the second degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084.

3. Any other controlled substance, except as lawfully sold, manufactured, or delivered, must be sentenced to pay a \$500 fine and to serve 100 hours of public service in addition to any other penalty prescribed by law.

(e) Except as authorized by this chapter, a person may not

19-00569-17

2017424__

1628 sell, manufacture, or deliver, or possess with intent to sell,
1629 manufacture, or deliver, a controlled substance not authorized
1630 by law in, on, or within 1,000 feet of a physical place for
1631 worship at which a church or religious organization regularly
1632 conducts religious services or within 1,000 feet of a
1633 convenience business as defined in s. 812.171. A person who
1634 violates this paragraph with respect to:

1635 1. A controlled substance named or described in s.
1636 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
1637 commits a felony of the first degree, punishable as provided in
1638 s. 775.082, s. 775.083, or s. 775.084.

1639 2. A controlled substance named or described in s.
1640 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
1641 (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
1642 the second degree, punishable as provided in s. 775.082, s.
1643 775.083, or s. 775.084.

1644 3. Any other controlled substance, except as lawfully sold,
1645 manufactured, or delivered, must be sentenced to pay a \$500 fine
1646 and to serve 100 hours of public service in addition to any
1647 other penalty prescribed by law.

1648 (f) Except as authorized by this chapter, a person may not
1649 sell, manufacture, or deliver, or possess with intent to sell,
1650 manufacture, or deliver, a controlled substance in, on, or
1651 within 1,000 feet of the real property comprising a public
1652 housing facility at any time. As used in this section, the term
1653 "real property comprising a public housing facility" means real
1654 property, as defined in s. 421.03(12), of a public corporation
1655 created as a housing authority pursuant to part I of chapter
1656 421. A person who violates this paragraph with respect to:

19-00569-17

2017424__

1657 1. A controlled substance named or described in s.
1658 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
1659 commits a felony of the first degree, punishable as provided in
1660 s. 775.082, s. 775.083, or s. 775.084.

1661 2. A controlled substance named or described in s.
1662 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
1663 (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
1664 the second degree, punishable as provided in s. 775.082, s.
1665 775.083, or s. 775.084.

1666 3. Any other controlled substance, except as lawfully sold,
1667 manufactured, or delivered, must be sentenced to pay a \$500 fine
1668 and to serve 100 hours of public service in addition to any
1669 other penalty prescribed by law.

1670 (h) Except as authorized by this chapter, a person may not
1671 sell, manufacture, or deliver, or possess with intent to sell,
1672 manufacture, or deliver, a controlled substance in, on, or
1673 within 1,000 feet of the real property comprising an assisted
1674 living facility, as that term is used in chapter 429. A person
1675 who violates this paragraph with respect to:

1676 1. A controlled substance named or described in s.
1677 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
1678 commits a felony of the first degree, punishable as provided in
1679 s. 775.082, s. 775.083, or s. 775.084.

1680 2. A controlled substance named or described in s.
1681 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
1682 (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
1683 the second degree, punishable as provided in s. 775.082, s.
1684 775.083, or s. 775.084.

1685 3. Any other controlled substance, except as lawfully sold,

19-00569-17

2017424__

1686 manufactured, or delivered, must be sentenced to pay a \$500 fine
1687 and to serve 100 hours of public service in addition to any
1688 other penalty prescribed by law.

1689 (2) (a) Except as authorized by this chapter and chapter
1690 499, a person may not purchase, or possess with intent to
1691 purchase, a controlled substance. A person who violates this
1692 provision with respect to:

1693 1. A controlled substance named or described in s.
1694 893.03(1) (a), (1) (b), (1) (d), (2) (a), (2) (b), or (2) (c) 4.
1695 commits a felony of the second degree, punishable as provided in
1696 s. 775.082, s. 775.083, or s. 775.084.

1697 2. A controlled substance named or described in s.
1698 893.03(1) (c), (2) (c) 1., (2) (c) 2., (2) (c) 3., (2) (c) 5., (2) (c) 6.,
1699 (2) (c) 7., (2) (c) 8., (2) (c) 9., (3), or (4) commits a felony of
1700 the third degree, punishable as provided in s. 775.082, s.
1701 775.083, or s. 775.084.

1702 3. A controlled substance named or described in s.
1703 893.03(5) commits a misdemeanor of the first degree, punishable
1704 as provided in s. 775.082 or s. 775.083.

1705 (4) Except as authorized by this chapter, a person 18 years
1706 of age or older may not deliver any controlled substance to a
1707 person younger than 18 years of age, use or hire a person
1708 younger than 18 years of age as an agent or employee in the sale
1709 or delivery of such a substance, or use such person to assist in
1710 avoiding detection or apprehension for a violation of this
1711 chapter. A person who violates this paragraph with respect to:

1712 (b) A controlled substance named or described in s.
1713 893.03(1) (c), (2) (c) 1., (2) (c) 2., (2) (c) 3., (2) (c) 5., (2) (c) 6.,
1714 (2) (c) 7., (2) (c) 8., (2) (c) 9., (3), or (4) commits a felony of

19-00569-17

2017424__

1715 the second degree, punishable as provided in s. 775.082, s.
1716 775.083, or s. 775.084.

1717
1718 Imposition of sentence may not be suspended or deferred, and the
1719 person so convicted may not be placed on probation.

1720 (5) A person may not bring into this state any controlled
1721 substance unless the possession of such controlled substance is
1722 authorized by this chapter or unless such person is licensed to
1723 do so by the appropriate federal agency. A person who violates
1724 this provision with respect to:

1725 (b) A controlled substance named or described in s.
1726 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
1727 (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
1728 the third degree, punishable as provided in s. 775.082, s.
1729 775.083, or s. 775.084.

1730 (7)(a) A person may not:

1731 1. Distribute or dispense a controlled substance in
1732 violation of this chapter.

1733 2. Refuse or fail to make, keep, or furnish any record,
1734 notification, order form, statement, invoice, or information
1735 required under this chapter.

1736 3. Refuse entry into any premises for any inspection or
1737 refuse to allow any inspection authorized by this chapter.

1738 4. Distribute a controlled substance named or described in
1739 s. 893.03(1) or (2) except pursuant to an order form as required
1740 by s. 893.06.

1741 5. Keep or maintain any store, shop, warehouse, dwelling,
1742 building, vehicle, boat, aircraft, or other structure or place
1743 which is resorted to by persons using controlled substances in

19-00569-17

2017424__

1744 violation of this chapter for the purpose of using these
1745 substances, or which is used for keeping or selling them in
1746 violation of this chapter.

1747 6. Use to his or her own personal advantage, or reveal, any
1748 information obtained in enforcement of this chapter except in a
1749 prosecution or administrative hearing for a violation of this
1750 chapter.

1751 7. Possess a prescription form unless it has been signed by
1752 the practitioner whose name appears printed thereon and
1753 completed. This subparagraph does not apply if the person in
1754 possession of the form is the practitioner whose name appears
1755 printed thereon, an agent or employee of that practitioner, a
1756 pharmacist, or a supplier of prescription forms who is
1757 authorized by that practitioner to possess those forms.

1758 8. Withhold information from a practitioner from whom the
1759 person seeks to obtain a controlled substance or a prescription
1760 for a controlled substance that the person making the request
1761 has received a controlled substance or a prescription for a
1762 controlled substance of like therapeutic use from another
1763 practitioner within the previous 30 days.

1764 9. Acquire or obtain, or attempt to acquire or obtain,
1765 possession of a controlled substance by misrepresentation,
1766 fraud, forgery, deception, or subterfuge.

1767 10. Affix any false or forged label to a package or
1768 receptacle containing a controlled substance.

1769 11. Furnish false or fraudulent material information in, or
1770 omit any material information from, any report or other document
1771 required to be kept or filed under this chapter or any record
1772 required to be kept by this chapter.

19-00569-17

2017424__

1773 12. Store anhydrous ammonia in a container that is not
 1774 approved by the United States Department of Transportation to
 1775 hold anhydrous ammonia or is not constructed in accordance with
 1776 sound engineering, agricultural, or commercial practices.

1777 13. With the intent to obtain a controlled substance or
 1778 combination of controlled substances that are not medically
 1779 necessary for the person or an amount of a controlled substance
 1780 or substances that is not medically necessary for the person,
 1781 obtain or attempt to obtain from a practitioner a controlled
 1782 substance or a prescription for a controlled substance by
 1783 misrepresentation, fraud, forgery, deception, subterfuge, or
 1784 concealment of a material fact. For purposes of this
 1785 subparagraph, a material fact includes whether the person has an
 1786 existing prescription for a controlled substance issued for the
 1787 same period of time by another practitioner or as described in
 1788 subparagraph 8.

1789 Section 21. For the purpose of incorporating the amendment
 1790 made by this act to section 893.03, Florida Statutes, in
 1791 references thereto, paragraphs (b), (c), and (e) of subsection
 1792 (3) of section 921.0022, Florida Statutes, are reenacted to
 1793 read:

1794 921.0022 Criminal Punishment Code; offense severity ranking
 1795 chart.—

1796 (3) OFFENSE SEVERITY RANKING CHART
 1797 (b) LEVEL 2

1798
 1799

Florida	Felony	Description
Statute	Degree	

19-00569-17

2017424__

1800

379.2431 3rd Possession of 11 or fewer
 (1) (e) 3. marine turtle eggs in violation
 of the Marine Turtle Protection
 Act.

1801

379.2431 3rd Possession of more than 11
 (1) (e) 4. marine turtle eggs in violation
 of the Marine Turtle Protection
 Act.

1802

403.413 (6) (c) 3rd Dumps waste litter exceeding
 500 lbs. in weight or 100 cubic
 feet in volume or any quantity
 for commercial purposes, or
 hazardous waste.

1803

517.07 (2) 3rd Failure to furnish a prospectus
 meeting requirements.

1804

590.28 (1) 3rd Intentional burning of lands.

1805

784.05 (3) 3rd Storing or leaving a loaded
 firearm within reach of minor
 who uses it to inflict injury
 or death.

1806

787.04 (1) 3rd In violation of court order,
 take, entice, etc., minor

19-00569-17

2017424__

1807

beyond state limits.

806.13(1)(b)3.

3rd

Criminal mischief; damage \$1,000 or more to public communication or any other public service.

1808

810.061(2)

3rd

Impairing or impeding telephone or power to a dwelling; facilitating or furthering burglary.

1809

810.09(2)(e)

3rd

Trespassing on posted commercial horticulture property.

1810

812.014(2)(c)1.

3rd

Grand theft, 3rd degree; \$300 or more but less than \$5,000.

1811

812.014(2)(d)

3rd

Grand theft, 3rd degree; \$100 or more but less than \$300, taken from unenclosed curtilage of dwelling.

1812

812.015(7)

3rd

Possession, use, or attempted use of an antishoplifting or inventory control device countermeasure.

1813

19-00569-17

2017424__

1814
1815
1816
1817
1818
1819
1820
1821

817.234(1)(a)2.	3rd	False statement in support of insurance claim.
817.481(3)(a)	3rd	Obtain credit or purchase with false, expired, counterfeit, etc., credit card, value over \$300.
817.52(3)	3rd	Failure to redeliver hired vehicle.
817.54	3rd	With intent to defraud, obtain mortgage note, etc., by false representation.
817.60(5)	3rd	Dealing in credit cards of another.
817.60(6)(a)	3rd	Forgery; purchase goods, services with false card.
817.61	3rd	Fraudulent use of credit cards over \$100 or more within 6 months.
826.04	3rd	Knowingly marries or has sexual intercourse with person to whom related.

19-00569-17

2017424__

1822

831.01 3rd Forgery.

1823

831.02 3rd Uttering forged instrument;
utters or publishes alteration
with intent to defraud.

1824

831.07 3rd Forging bank bills, checks,
drafts, or promissory notes.

1825

831.08 3rd Possessing 10 or more forged
notes, bills, checks, or
drafts.

1826

831.09 3rd Uttering forged notes, bills,
checks, drafts, or promissory
notes.

1827

831.11 3rd Bringing into the state forged
bank bills, checks, drafts, or
notes.

1828

832.05 (3) (a) 3rd Cashing or depositing item with
intent to defraud.

1829

843.08 3rd False personation.

893.13 (2) (a) 2. 3rd Purchase of any s.
893.03 (1) (c), (2) (c) 1.,
(2) (c) 2., (2) (c) 3., (2) (c) 5.,

19-00569-17

2017424__

(2) (c) 6., (2) (c) 7., (2) (c) 8.,
 (2) (c) 9., (3), or (4) drugs
 other than cannabis.

1830

893.147 (2) 3rd Manufacture or delivery of drug
 paraphernalia.

1831

1832 (c) LEVEL 3

1833

1834

Florida	Felony	Description
Statute	Degree	

1835

119.10 (2) (b) 3rd Unlawful use of confidential
 information from police
 reports.

1836

316.066 3rd Unlawfully obtaining or using
 (3) (b) - (d) confidential crash reports.

1837

316.193 (2) (b) 3rd Felony DUI, 3rd conviction.

1838

316.1935 (2) 3rd Fleeing or attempting to elude
 law enforcement officer in
 patrol vehicle with siren and
 lights activated.

1839

319.30 (4) 3rd Possession by junkyard of motor
 vehicle with identification

19-00569-17

2017424__

1840
1841
1842
1843
1844
1845
1846
1847

number plate removed.

- 319.33(1)(a) 3rd Alter or forge any certificate of title to a motor vehicle or mobile home.
- 319.33(1)(c) 3rd Procure or pass title on stolen vehicle.
- 319.33(4) 3rd With intent to defraud, possess, sell, etc., a blank, forged, or unlawfully obtained title or registration.
- 327.35(2)(b) 3rd Felony BUI.
- 328.05(2) 3rd Possess, sell, or counterfeit fictitious, stolen, or fraudulent titles or bills of sale of vessels.
- 328.07(4) 3rd Manufacture, exchange, or possess vessel with counterfeit or wrong ID number.
- 376.302(5) 3rd Fraud related to reimbursement for cleanup expenses under the Inland Protection Trust Fund.

19-00569-17

2017424__

379.2431
(1) (e) 5.

3rd Taking, disturbing, mutilating,
destroying, causing to be
destroyed, transferring,
selling, offering to sell,
molesting, or harassing marine
turtles, marine turtle eggs, or
marine turtle nests in
violation of the Marine Turtle
Protection Act.

1848

379.2431
(1) (e) 6.

3rd Soliciting to commit or
conspiring to commit a
violation of the Marine Turtle
Protection Act.

1849

400.9935 (4) (a)
or (b)

3rd Operating a clinic, or offering
services requiring licensure,
without a license.

1850

400.9935 (4) (e)

3rd Filing a false license
application or other required
information or failing to
report information.

1851

440.1051 (3)

3rd False report of workers'
compensation fraud or
retaliation for making such a
report.

1852

19-00569-17

2017424__

1853	501.001 (2) (b)	2nd	Tampers with a consumer product or the container using materially false/misleading information.
1854	624.401 (4) (a)	3rd	Transacting insurance without a certificate of authority.
1855	624.401 (4) (b) 1.	3rd	Transacting insurance without a certificate of authority; premium collected less than \$20,000.
1856	626.902 (1) (a) & (b)	3rd	Representing an unauthorized insurer.
1857	697.08	3rd	Equity skimming.
1858	790.15 (3)	3rd	Person directs another to discharge firearm from a vehicle.
1859	806.10 (1)	3rd	Maliciously injure, destroy, or interfere with vehicles or equipment used in firefighting.
	806.10 (2)	3rd	Interferes with or assaults firefighter in performance of duty.

19-00569-17

2017424__

1860	810.09 (2) (c)	3rd	Trespass on property other than structure or conveyance armed with firearm or dangerous weapon.
1861	812.014 (2) (c) 2.	3rd	Grand theft; \$5,000 or more but less than \$10,000.
1862	812.0145 (2) (c)	3rd	Theft from person 65 years of age or older; \$300 or more but less than \$10,000.
1863	815.04 (5) (b)	2nd	Computer offense devised to defraud or obtain property.
1864	817.034 (4) (a) 3.	3rd	Engages in scheme to defraud (Florida Communications Fraud Act), property valued at less than \$20,000.
1865	817.233	3rd	Burning to defraud insurer.
1866	817.234 (8) (b) & (c)	3rd	Unlawful solicitation of persons involved in motor vehicle accidents.
1867	817.234 (11) (a)	3rd	Insurance fraud; property value less than \$20,000.

19-00569-17

2017424__

1868	817.236	3rd	Filing a false motor vehicle insurance application.
1869	817.2361	3rd	Creating, marketing, or presenting a false or fraudulent motor vehicle insurance card.
1870	817.413 (2)	3rd	Sale of used goods as new.
1871	817.505 (4)	3rd	Patient brokering.
1872	828.12 (2)	3rd	Tortures any animal with intent to inflict intense pain, serious physical injury, or death.
1873	831.28 (2) (a)	3rd	Counterfeiting a payment instrument with intent to defraud or possessing a counterfeit payment instrument.
1874	831.29	2nd	Possession of instruments for counterfeiting driver licenses or identification cards.
1875	838.021 (3) (b)	3rd	Threatens unlawful harm to public servant.

19-00569-17

2017424__

1876

843.19 3rd Injure, disable, or kill police dog or horse.

1877

860.15(3) 3rd Overcharging for repairs and parts.

1878

870.01(2) 3rd Riot; inciting or encouraging.

1879

893.13(1)(a)2. 3rd Sell, manufacture, or deliver cannabis (or other s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) drugs).

1880

893.13(1)(d)2. 2nd Sell, manufacture, or deliver s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) drugs within 1,000 feet of university.

1881

893.13(1)(f)2. 2nd Sell, manufacture, or deliver s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) drugs

19-00569-17

2017424__

1882

within 1,000 feet of public housing facility.

893.13(4)(c)

3rd

Use or hire of minor; deliver to minor other controlled substances.

1883

893.13(6)(a)

3rd

Possession of any controlled substance other than felony possession of cannabis.

1884

893.13(7)(a)8.

3rd

Withhold information from practitioner regarding previous receipt of or prescription for a controlled substance.

1885

893.13(7)(a)9.

3rd

Obtain or attempt to obtain controlled substance by fraud, forgery, misrepresentation, etc.

1886

893.13(7)(a)10.

3rd

Affix false or forged label to package of controlled substance.

1887

893.13(7)(a)11.

3rd

Furnish false or fraudulent material information on any document or record required by chapter 893.

19-00569-17 2017424__

1893

918.13(1)(a) 3rd Alter, destroy, or conceal investigation evidence.

1894

944.47 (1)(a)1. & 2. 3rd Introduce contraband to correctional facility.

1895

944.47(1)(c) 2nd Possess contraband while upon the grounds of a correctional institution.

1896

985.721 3rd Escapes from a juvenile facility (secure detention or residential commitment facility).

1897

(e) LEVEL 5

1898

1899

Florida Statute Felony Degree Description

1900

316.027(2)(a) 3rd Accidents involving personal injuries other than serious bodily injury, failure to stop; leaving scene.

1901

316.1935(4)(a) 2nd Aggravated fleeing or eluding.

1902

316.80(2) 2nd Unlawful conveyance of fuel;

	19-00569-17		2017424__
1903			obtaining fuel fraudulently.
	322.34 (6)	3rd	Careless operation of motor vehicle with suspended license, resulting in death or serious bodily injury.
1904			
	327.30 (5)	3rd	Vessel accidents involving personal injury; leaving scene.
1905			
	379.365 (2) (c) 1.	3rd	Violation of rules relating to: willful molestation of stone crab traps, lines, or buoys; illegal bartering, trading, or sale, conspiring or aiding in such barter, trade, or sale, or supplying, agreeing to supply, aiding in supplying, or giving away stone crab trap tags or certificates; making, altering, forging, counterfeiting, or reproducing stone crab trap tags; possession of forged, counterfeit, or imitation stone crab trap tags; and engaging in the commercial harvest of stone crabs while license is suspended or revoked.
1906			

				2017424__
1907	19-00569-17	379.367 (4)	3rd	Willful molestation of a commercial harvester's spiny lobster trap, line, or buoy.
1908		379.407 (5) (b) 3.	3rd	Possession of 100 or more undersized spiny lobsters.
1909		381.0041 (11) (b)	3rd	Donate blood, plasma, or organs knowing HIV positive.
1910		440.10 (1) (g)	2nd	Failure to obtain workers' compensation coverage.
1911		440.105 (5)	2nd	Unlawful solicitation for the purpose of making workers' compensation claims.
1912		440.381 (2)	2nd	Submission of false, misleading, or incomplete information with the purpose of avoiding or reducing workers' compensation premiums.
1913		624.401 (4) (b) 2.	2nd	Transacting insurance without a certificate or authority; premium collected \$20,000 or more but less than \$100,000.
		626.902 (1) (c)	2nd	Representing an unauthorized

19-00569-17

2017424__

1914			insurer; repeat offender.
1915	790.01 (2)	3rd	Carrying a concealed firearm.
1916	790.162	2nd	Threat to throw or discharge destructive device.
1917	790.163 (1)	2nd	False report of bomb, explosive, weapon of mass destruction, or use of firearms in violent manner.
1918	790.221 (1)	2nd	Possession of short-barreled shotgun or machine gun.
1919	790.23	2nd	Felons in possession of firearms, ammunition, or electronic weapons or devices.
1920	796.05 (1)	2nd	Live on earnings of a prostitute; 1st offense.
1921	800.04 (6) (c)	3rd	Lewd or lascivious conduct; offender less than 18 years of age.
	800.04 (7) (b)	2nd	Lewd or lascivious exhibition; offender 18 years of age or older.

19-00569-17

2017424__

1922	806.111 (1)	3rd	Possess, manufacture, or dispense fire bomb with intent to damage any structure or property.
1923	812.0145 (2) (b)	2nd	Theft from person 65 years of age or older; \$10,000 or more but less than \$50,000.
1924	812.015 (8)	3rd	Retail theft; property stolen is valued at \$300 or more and one or more specified acts.
1925	812.019 (1)	2nd	Stolen property; dealing in or trafficking in.
1926	812.131 (2) (b)	3rd	Robbery by sudden snatching.
1927	812.16 (2)	3rd	Owning, operating, or conducting a chop shop.
1928	817.034 (4) (a) 2.	2nd	Communications fraud, value \$20,000 to \$50,000.
1929	817.234 (11) (b)	2nd	Insurance fraud; property value \$20,000 or more but less than \$100,000.
1930			

19-00569-17 2017424__

1931 817.2341(1), 3rd Filing false financial
 (2) (a) & (3) (a) statements, making false
 entries of material fact or
 false statements regarding
 property values relating to the
 solvency of an insuring entity.

1932 817.568(2) (b) 2nd Fraudulent use of personal
 identification information;
 value of benefit, services
 received, payment avoided, or
 amount of injury or fraud,
 \$5,000 or more or use of
 personal identification
 information of 10 or more
 persons.

1933 817.611(2) (a) 2nd Traffic in or possess 5 to 14
 counterfeit credit cards or
 related documents.

1934 817.625(2) (b) 2nd Second or subsequent fraudulent
 use of scanning device or
 reencoder.

1935 825.1025(4) 3rd Lewd or lascivious exhibition
 in the presence of an elderly
 person or disabled adult.

	19-00569-17			2017424__
	827.071 (4)	2nd	Possess with intent to promote any photographic material, motion picture, etc., which includes sexual conduct by a child.	
1936				
	827.071 (5)	3rd	Possess, control, or intentionally view any photographic material, motion picture, etc., which includes sexual conduct by a child.	
1937				
	839.13 (2) (b)	2nd	Falsifying records of an individual in the care and custody of a state agency involving great bodily harm or death.	
1938				
	843.01	3rd	Resist officer with violence to person; resist arrest with violence.	
1939				
	847.0135 (5) (b)	2nd	Lewd or lascivious exhibition using computer; offender 18 years or older.	
1940				
	847.0137 (2) & (3)	3rd	Transmission of pornography by electronic device or equipment.	
1941				

19-00569-17

2017424__

1942

847.0138 (2) & (3) 3rd Transmission of material harmful to minors to a minor by electronic device or equipment.

1943

874.05(1)(b) 2nd Encouraging or recruiting another to join a criminal gang; second or subsequent offense.

1944

874.05(2)(a) 2nd Encouraging or recruiting person under 13 years of age to join a criminal gang.

1945

893.13(1)(a)1. 2nd Sell, manufacture, or deliver cocaine (or other s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4. drugs).

893.13(1)(c)2. 2nd Sell, manufacture, or deliver cannabis (or other s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) drugs) within 1,000 feet of a child care facility, school, or state, county, or municipal park or publicly owned

19-00569-17

2017424__

1946

recreational facility or
community center.

893.13(1)(d)1.

1st

Sell, manufacture, or deliver
cocaine (or other s.
893.03(1)(a), (1)(b), (1)(d),
(2)(a), (2)(b), or (2)(c)4.
drugs) within 1,000 feet of
university.

1947

893.13(1)(e)2.

2nd

Sell, manufacture, or deliver
cannabis or other drug
prohibited under s.
893.03(1)(c), (2)(c)1.,
(2)(c)2., (2)(c)3., (2)(c)5.,
(2)(c)6., (2)(c)7., (2)(c)8.,
(2)(c)9., (3), or (4) within
1,000 feet of property used for
religious services or a
specified business site.

1948

893.13(1)(f)1.

1st

Sell, manufacture, or deliver
cocaine (or other s.
893.03(1)(a), (1)(b), (1)(d),
or (2)(a), (2)(b), or (2)(c)4.
drugs) within 1,000 feet of
public housing facility.

1949

893.13(4)(b)

2nd

Use or hire of minor; deliver

19-00569-17

2017424__

to minor other controlled
substance.

1950

893.1351(1)

3rd

Ownership, lease, or rental for
trafficking in or manufacturing
of controlled substance.

1951

1952

Section 22. This act shall take effect October 1, 2017.